Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-490 in Relapsed or Refractory Non-Hodgkin Lymphoma
NCT06845241Phase 2Not yet recruiting
- Sponsor
- InnoCare Pharma
- Start
- Feb 2025
- Primary completion
- Jul 2028
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ICP-490 in non-Hodgkin lymphoma (NHL), sponsored by InnoCare Pharma. Primary endpoints: Incidence, type, and severity of adverse events (AEs) at 3 years, Incidence, type, and severity of dose-limiting toxicities at 3 years and 2 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ICP-490
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06845241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06845241.